1. Home
  2. KOS vs ABCL Comparison

KOS vs ABCL Comparison

Compare KOS & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kosmos Energy Ltd. (DE)

KOS

Kosmos Energy Ltd. (DE)

HOLD

Current Price

$2.65

Market Cap

1.8B

Sector

Energy

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$5.73

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOS
ABCL
Founded
2003
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
KOS
ABCL
Price
$2.65
$5.73
Analyst Decision
Hold
Strong Buy
Analyst Count
6
5
Target Price
$1.91
$8.40
AVG Volume (30 Days)
16.4M
7.5M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.91
EPS
N/A
N/A
Revenue
$1,288,352,000.00
$75,128,000.00
Revenue This Year
$27.11
N/A
Revenue Next Year
N/A
$21.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
160.56
52 Week Low
$0.84
$2.75
52 Week High
$3.34
$8.44

Technical Indicators

Market Signals
Indicator
KOS
ABCL
Relative Strength Index (RSI) 58.95 42.26
Support Level $2.33 $5.23
Resistance Level $2.69 $6.79
Average True Range (ATR) 0.18 0.59
MACD 0.06 -0.24
Stochastic Oscillator 95.54 7.07

Price Performance

Historical Comparison
KOS
ABCL

About KOS Kosmos Energy Ltd. (DE)

Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: